Investigational drug · Phase 2
MK-6916
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pain Management.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "MK-6916"
First trial start
2026
Nov 2, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MK-6916", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pain Management
Approved drugs for the same conditions: Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "MK-6916" as an intervention, largest first.
- A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07862595 · 380 participants (planned) · Start Nov 2, 2026 · Primary completion Jun 10, 2027
Drug: MK-6916; Hydrocodone/acetaminophen (HB/APAP) and 2 more · For: Pain Management
Sites: Miami, Florida; Tampa, Florida; Atlanta, Georgia · 9 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06818968 · 37 participants · Start Feb 27, 2025 · Primary completion Aug 8, 2025
Drug: MK-6916; Diltiazem · For: Healthy
Sites: Madison, Wisconsin
- A Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease Compared to Healthy Controls (MK-6916-013)Not yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07922174 · 32 participants (planned) · Start Dec 11, 2026 · Primary completion Aug 6, 2027
Drug: MK-6916 · For: Healthy; Renal Impairment
- A Clinical Trial of MK-6916 With Midazolam and Rosuvastatin in Healthy Participants (MK-6916-012)Not yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07862621 · 18 participants (planned) · Start Nov 30, 2026 · Primary completion Feb 9, 2027
Drug: Midazolam; Rosuvastatin and 1 more · For: Healthy
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Pain Management
- EtoricoxibPhase 34 trials
Laboratorios Silanes S.A. de C.V. · Gout Arthritis, Gout Attack, Acute Low-back Pain
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.